Cochrane · systematic review · CD004154
Clobazam add‐on therapy for drug‐resistant epilepsy
Bresnahan, R, Martin‐McGill, KJ, Williamson, J, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 33.3%Ungraded 0 · 0%Very low 4 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Clobazam compared to Placebo in the management of drug‐resistant epilepsy
Population: children or adults with drug‐resistant epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% reduction in seizure frequency Clobazam vs Placebo | no estimate extracted | 2 studies · 47 participants | Very low Downgraded: risk of bias |
Seizure Freedom Clobazam vs Placebo | no estimate extracted | 3 studies · 175 participants | Very low Downgraded: risk of bias |
Treatment withdrawal Clobazam vs Placebo | no estimate extracted | 4 studies · 197 participants | Very low Downgraded: risk of bias |
Treatment withdrawal due to adverse events Clobazam vs Placebo | no estimate extracted | 2 studies · 150 participants | Very low Downgraded: risk of bias |
50% reduction in generalised‐onset seizure frequency Not measured Clobazam vs Placebo | no estimate extracted | NR | No studies |
50% reduction in focal‐onset seizure frequency Not measured Clobazam vs Placebo | no estimate extracted | NR | No studies |